CLAIMS

1. A pharmaceutical composition comprising:

a pharmaceutically acceptable carrier or diluent; and,

one or more compounds having a structure selected from the group consisting of mifepristone, Formulas D1-D20, and pharmaceutically acceptable salts thereof;

wherein said compound is present in an amount effective to inhibit HIV in an individual, said composition being in the form selected from the group consisting of:

a composition formulated as a transdermal patch;

a composition formulated as a subdermal delivery system; and

a controlled/sustained release formulation.

2. The pharmaceutical composition of claim 1 further comprising one or more compounds having a structure selected from the group consisting: zidovudine (AZT), abacavir, 3TC, d4T, ddI, ddC, efavirenz, nevirapine, delavidine, amprenavir, Indinavir, Lopinavir, nelfinavir, ritonavir, sanquinavir, acyclovir, ganciclovir, foscarnet, interferon alpha-2a, and interferon alpha-2b.

3. The pharmaceutical composition of claims 1 or 2 wherein said composition being in the form of a composition formulated as a transdermal patch.

4. The pharmaceutical composition of claims 1 or 2 wherein said composition being in the form of a composition formulated as a subdermal delivery system.

5. The pharmaceutical composition of claims 1 or 2 wherein said composition being in the form of a controlled/sustained release formulation.

6. The pharmaceutical composition of any of claims 1 to 5 wherein said composition comprises mifepristone.

7. The pharmaceutical composition of any of claims 1 to 5 wherein said composition comprises 10-120 mg mifepristone.

8. The pharmaceutical composition of any of claims 1 to 5 wherein said composition comprises 60 mg mifepristone.

9. The pharmaceutical composition of any of claims 1 to 5 wherein said composition comprises 30 mg mifepristone.

10. A method of treating an individual who is infected with HIV comprising the step of administering to said individual a therapeutically effective amount of a composition according to any one of claims 1-9.

11. The method of claim 10 wherein said individual is administered mifepristone at a dosage level to achieve steady-state serum drug concentration of 17-430 ng/ml.

12. A method of preventing HIV infection in an individual identified as being a high risk individual, the method comprising the step of administering to said individual a prophylactically effective amount of a composition according to claims 1-9.

13. A method of claim 12 wherein said individual is administered mifepristone at a dosage level to achieve steady-state serum drug concentration of 17-430 ng/ml.

14. A pharmaceutical composition comprising 10-120 mg mifepristone, a pharmaceutically acceptable salt thereof or a combination thereof.

15. The pharmaceutical composition of claim 14 wherein said composition comprises 60 mg mifepristone.

16. The pharmaceutical composition of any of claims 14 to 15 wherein said composition comprises 30 mg mifepristone.

17. A method of treating an individual who is infected with HIV comprising the step of administering to said individual a therapeutically effective amount of a composition according to any one of claims 14-16.

18. The method of claim 17 wherein said individual is administered mifepristone at a dosage level to achieve steady-state serum drug concentration of 17-430 ng/ml.

19. A method of preventing HIV infection in an individual identified as being a high risk individual, the method comprising the step of administering to said individual a prophylactically effective amount of a composition according to any one of claims 14-16.

20. The method of claim 19 wherein said individual is administered mifepristone at a dosage level to achieve steady-state serum drug concentration of 17-430 ng/ml.

21. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and, one or more compounds having a structure selected from the group consisting of: hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite, Compounds D1- D20, and pharmaceutically acceptable salts thereof; wherein said compound is present in an amount effective to inhibit HIV in an individual.

22. The pharmaceutical composition of claim 21 further comprising one or more compounds having a structure selected from the group consisting: mifepristone, zidovudine (AZT), abacavir, 3TC, d4T, ddl, ddC, efavirenz, nevirapine, delavidine, amprenavir, Indinavir, Lopinavir, nelfinavir, ritonavir, sanquinavir, acyclovir, ganciclovir, foscarnet, interferon alpha-2a, and interferon alpha-2b

23. The pharmaceutical composition of any one of claims 21-22 comprising 10-120 mg hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite, a pharmaceutically acceptable salt thereof or a combination thereof.

24. The pharmaceutical composition of any one of claims 21-23 wherein said composition comprises 60 mg hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite a pharmaceutically acceptable salt thereof or a combination thereof.

25. The pharmaceutical composition of any of any one of claims 21-24 wherein said composition comprises 30 mg hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite a pharmaceutically acceptable salt thereof or a combination thereof.. .

26. A method of treating an individual who is infected with HIV comprising the step of administering to said individual a therapeutically effective amount of a composition according to any one of claims 21-25.

27. A method of preventing HIV infection in an individual identified as being a high risk individual, the method comprising the step of administering to said individual a prophylactically effective amount of a composition according to any one of claims 21-26.